Clinical characteristics and prognostic value for outcome
| Clinical characteristics . | No. patients (of 89) . | Outcome . | |
|---|---|---|---|
| pEFS at 5 y (SE) . | P univariate . | ||
| Sex | |||
| Male | 62 | 0.77 (0.05) | .58 |
| Female | 27 | 0.74 (0.09) | |
| Stage | |||
| I | 8 | 1.00 (0.00) | |
| II | 20 | 0.79 (0.09) | .134-150 |
| III | 55 | 0.74 (0.06) | |
| IV | 6 | 0.50 (0.20) | |
| Immunology | |||
| T | 40 | 0.67 (0.08) | .17 |
| B | 5 | 0.60 (0.2) | (T versus null) |
| Null | 31 | 0.84 (0.07) | |
| Not available | 13 | 0.92 (0.04) | |
| ALK-1 | |||
| Positive | 35 | 0.82 (0.07) | .33 |
| Negative | 8 | 0.62 (0.17) | (Positive vs negative) |
| Not available | 46 | 0.73 (0.06) | |
| Tumor sites | |||
| Lymph nodes | 80 | 0.74 (0.05) | .18 |
| Mediastinal mass | 28 | 0.70 (0.09) | .42 |
| Skin | 16 | 0.56 (0.12) | .07 |
| Bone | 14 | 0.93 (0.04) | .13 |
| Lung | 13 | 0.62 (0.13) | .03 |
| Splenomegaly | 10 | 0.60 (0.15) | .04 |
| Hepatomegaly | 22 | 0.73 (0.09) | .64 |
| Soft tissue | 13 | 0.84 (0.08) | .47 |
| Bone marrow | 5 | 2 relapses (new sites) | — |
| Central nervous system | 1 | 1 relapse CNS | — |
| Malignant effusions | 13 | 0.69 (0.13) | .75 |
| B-symptoms | 46 | 0.67 (0.07) | .04 |
| Lactate dehydrogenase | |||
| < 500 U/L | 77 | 0.73 (0.05) | — |
| ≥ 500 U/L | 8 | ||
| Not available | 4 | ||
| Clinical characteristics . | No. patients (of 89) . | Outcome . | |
|---|---|---|---|
| pEFS at 5 y (SE) . | P univariate . | ||
| Sex | |||
| Male | 62 | 0.77 (0.05) | .58 |
| Female | 27 | 0.74 (0.09) | |
| Stage | |||
| I | 8 | 1.00 (0.00) | |
| II | 20 | 0.79 (0.09) | .134-150 |
| III | 55 | 0.74 (0.06) | |
| IV | 6 | 0.50 (0.20) | |
| Immunology | |||
| T | 40 | 0.67 (0.08) | .17 |
| B | 5 | 0.60 (0.2) | (T versus null) |
| Null | 31 | 0.84 (0.07) | |
| Not available | 13 | 0.92 (0.04) | |
| ALK-1 | |||
| Positive | 35 | 0.82 (0.07) | .33 |
| Negative | 8 | 0.62 (0.17) | (Positive vs negative) |
| Not available | 46 | 0.73 (0.06) | |
| Tumor sites | |||
| Lymph nodes | 80 | 0.74 (0.05) | .18 |
| Mediastinal mass | 28 | 0.70 (0.09) | .42 |
| Skin | 16 | 0.56 (0.12) | .07 |
| Bone | 14 | 0.93 (0.04) | .13 |
| Lung | 13 | 0.62 (0.13) | .03 |
| Splenomegaly | 10 | 0.60 (0.15) | .04 |
| Hepatomegaly | 22 | 0.73 (0.09) | .64 |
| Soft tissue | 13 | 0.84 (0.08) | .47 |
| Bone marrow | 5 | 2 relapses (new sites) | — |
| Central nervous system | 1 | 1 relapse CNS | — |
| Malignant effusions | 13 | 0.69 (0.13) | .75 |
| B-symptoms | 46 | 0.67 (0.07) | .04 |
| Lactate dehydrogenase | |||
| < 500 U/L | 77 | 0.73 (0.05) | — |
| ≥ 500 U/L | 8 | ||
| Not available | 4 | ||
Only subgroups of at least 10 patients were included in the analysis of event-free survival.
CNS indicates central nervous system; pEFS probability of event-free survival; ALK-1, anaplastic lymphoma kinase 1.
P (stage I + II, pEFS 0.85, SE 0.07, vs stage III + IV, pEFS 0.72, SE 0.06).